Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Other Non-Current Assets (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Other Non-Current Assets for 4 consecutive years, with $2.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Assets rose 309.56% to $2.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.3 million, a 309.56% increase, with the full-year FY2024 number at $2.8 million, up 40.07% from a year prior.
  • Other Non-Current Assets was $2.3 million for Q3 2025 at Century Therapeutics, down from $2.7 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $2.8 million in Q2 2024 to a low of $544000.0 in Q1 2024.
  • A 4-year average of $1.9 million and a median of $2.0 million in 2022 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: tumbled 72.51% in 2024, then surged 410.11% in 2025.
  • Century Therapeutics' Other Non-Current Assets stood at $2.0 million in 2022, then changed by 0.0% to $2.0 million in 2023, then skyrocketed by 40.07% to $2.8 million in 2024, then dropped by 16.52% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Other Non-Current Assets are $2.3 million (Q3 2025), $2.7 million (Q2 2025), and $2.8 million (Q1 2025).